Van ECK Associates Corp Sells 78,228 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Van ECK Associates Corp lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 98.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,546 shares of the company's stock after selling 78,228 shares during the quarter. Van ECK Associates Corp's holdings in CRISPR Therapeutics were worth $71,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Global Trust Asset Management LLC raised its stake in shares of CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Larson Financial Group LLC raised its stake in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company's stock worth $31,000 after buying an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC increased its stake in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company's stock valued at $33,000 after purchasing an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of CRISPR Therapeutics during the second quarter valued at approximately $35,000. Finally, Denver PWM LLC purchased a new stake in shares of CRISPR Therapeutics during the second quarter valued at approximately $45,000. Institutional investors own 69.20% of the company's stock.

Analyst Ratings Changes

CRSP has been the topic of a number of recent analyst reports. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They set a "buy" rating and a $90.00 price target on the stock. Barclays dropped their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a report on Wednesday, November 6th. Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Truist Financial dropped their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, August 12th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Hold" and an average price target of $74.94.

CRISPR Therapeutics Price Performance

Shares of CRSP stock traded down $2.94 on Thursday, hitting $46.85. 1,955,295 shares of the stock traded hands, compared to its average volume of 1,473,070. The firm has a market cap of $4.00 billion, a price-to-earnings ratio of -16.66 and a beta of 1.67. The firm has a 50 day simple moving average of $47.80 and a two-hundred day simple moving average of $52.12. CRISPR Therapeutics AG has a 52 week low of $43.42 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. During the same period last year, the company posted ($1.41) EPS. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.2 EPS for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares of the company's stock, valued at $2,896,989.16. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the business's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company's stock, valued at approximately $10,484,271.20. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,382 shares of company stock valued at $1,917,679 in the last three months. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.